8 RECIST RECIST placebo click to read.

Data from a Phase II study of BIBF 1120 response in patients with ovarian cancer who presented at least second-line chemotherapy at ASCO in Orlando click to read read more . The study indicated a potential delay of disease progression: with BIBF 1120 the median time to progression was 4.8 and 2.8 RECIST RECIST placebo.2 BIBF 1120 is an oral supplement that by simultaneously inhibiting vascular endothelial growth factor receptors , works platelet-derived growth factor receptors , and fibroblast growth factor receptors – angiogenesis all factors known decisive in the formation of blood vessels, a process. 13 are 13 are.

Source Boehringer IngelheimBoehringer Ingelheim will data on data on the company’s two lead oncology compounds, BIBW 2992 and BIBF 1120** 2009* at the annual meeting of the American Society of Clinical Oncology , the company announced today. Two studies in the LUX-Lung clinical development program for BIBW 2992 and a Phase II study of BIBF 1120 in patients with advanced ovarian cancer will be presented.

In addition, Unite for Climate are to combine least 150 school around the world in September 2009. The connection schoolroom project is, which dialogue on climate change among school children and is granted by The Energy and Resources Institute of the Earth Institute at Columbia and the Mediterranean Sea Centre of Sustainable Development supports, among other partners.